Successful Treatment of Paediatric Necrobiosis Lipoidica With Baricitinib

ABSTRACT Necrobiosis lipoidica (NL) is a rare, chronic granulomatous condition that typically presents as sharply demarcated plaques with telangiectasia and atrophic centres. Paediatric cases are uncommon, and treatment options often fail to address refractory cases. We report a 13‐year‐old girl with progressive NL lesions that responded successfully to oral baricitinib, a Janus kinase inhibitor. Initial management with topical and systemic corticosteroids failed, but baricitinib led to significant lesion improvement within 6 months. This case highlights the potential of baricitinib in refractory paediatric NL and underscores the need for further research on its long‐term efficacy and safety.